Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kyverna Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KYTX
Nasdaq
8731
https://kyvernatx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kyverna Therapeutics Inc
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
- Apr 11th, 2024 9:01 pm
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
- Mar 29th, 2024 6:59 pm
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
- Mar 26th, 2024 8:05 pm
Why That Hot Biotech IPO Could Be a Winner
- Mar 14th, 2024 11:00 am
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
- Mar 8th, 2024 12:26 am
How Kyverna is positioned for success on autoimmune therapy: CEO
- Mar 7th, 2024 11:14 pm
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Feb 12th, 2024 9:39 pm
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
- Feb 8th, 2024 3:29 am
Scroll